QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
QQQ   438.28 (+0.69%)
AAPL   181.44 (+0.01%)
MSFT   408.47 (+0.18%)
META   489.80 (+1.19%)
GOOGL   137.40 (+0.75%)
AMZN   174.88 (+0.99%)
TSLA   201.81 (-0.11%)
NVDA   795.89 (+2.48%)
NIO   5.66 (+4.24%)
AMD   187.40 (+6.15%)
BABA   74.33 (-0.35%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.61 (-0.11%)
CGC   3.34 (-0.60%)
GE   155.84 (+0.15%)
DIS   111.70 (+0.81%)
AMC   4.42 (-11.42%)
PFE   26.97 (-0.26%)
PYPL   60.86 (+1.01%)
XOM   104.28 (-0.04%)
NASDAQ:NAUT

Nautilus Biotechnology (NAUT) Stock Price, News & Analysis

$2.77
-0.03 (-1.07%)
(As of 10:22 AM ET)
Today's Range
$2.72
$2.90
50-Day Range
$2.61
$3.39
52-Week Range
$2.00
$4.65
Volume
10,909 shs
Average Volume
73,481 shs
Market Capitalization
$346.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Nautilus Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
116.6% Upside
$6.00 Price Target
Short Interest
Bearish
2.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of Nautilus Biotechnology in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.59) to ($0.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.05 out of 5 stars

Medical Sector

819th out of 958 stocks

Analytical Instruments Industry

24th out of 29 stocks


NAUT stock logo

About Nautilus Biotechnology Stock (NASDAQ:NAUT)

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was incorporated in 2016 and is headquartered in Seattle, Washington.

NAUT Stock Price History

NAUT Stock News Headlines

Q4 2023 Nautilus Biotechnology Inc Earnings Call
Detecting Cancer in Mere Seconds: Early Investment Opportunity
A revolutionary cancer diagnostic tool is likely to come to fruition with anticipated FDA approval expected in just months. With the ability to detect cancer's "molecular fingerprint" in just seconds, it also offers far superior accuracy to current detection methods and reduces the need for invasive biopsies.
Game-Changing Cancer Tech Nears FDA Completion
In the world of tech advancements, a new player could outshine even AI. It's a revolutionary technology with the aim of transforming cancer detection. Imagine the leap from basic reading glasses to cutting-edge VR; that's the scale of innovation we're talking about. FDA review is in its final stages and it could become the gold standard before we know it.
Nautilus Biotechnology Inc Ordinary Shares
Nautilus Biotechnology Inc.
See More Headlines
Receive NAUT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nautilus Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NAUT
Fax
N/A
Employees
160
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+110.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-57,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.53 per share

Miscellaneous

Free Float
71,844,000
Market Cap
$356.11 million
Optionable
Optionable
Beta
1.20
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives















NAUT Stock Analysis - Frequently Asked Questions

Should I buy or sell Nautilus Biotechnology stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nautilus Biotechnology in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NAUT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NAUT, but not buy additional shares or sell existing shares.
View NAUT analyst ratings
or view top-rated stocks.

What is Nautilus Biotechnology's stock price target for 2024?

1 brokers have issued twelve-month price targets for Nautilus Biotechnology's shares. Their NAUT share price targets range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 116.6% from the stock's current price.
View analysts price targets for NAUT
or view top-rated stocks among Wall Street analysts.

How have NAUT shares performed in 2024?

Nautilus Biotechnology's stock was trading at $2.99 on January 1st, 2024. Since then, NAUT stock has decreased by 7.4% and is now trading at $2.77.
View the best growth stocks for 2024 here
.

When is Nautilus Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our NAUT earnings forecast
.

How were Nautilus Biotechnology's earnings last quarter?

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) issued its earnings results on Wednesday, February, 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.02. During the same period in the previous year, the business posted ($0.11) earnings per share.

Who are Nautilus Biotechnology's major shareholders?

Nautilus Biotechnology's stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (10.08%), Vanguard Group Inc. (2.26%), Dimensional Fund Advisors LP (0.32%), Nuveen Asset Management LLC (0.15%), Charles Schwab Investment Management Inc. (0.11%) and Barclays PLC (0.09%). Insiders that own company stock include Anna Mowry, Gwen E Weld, Life Sciences Maste Perceptive, Matthew B Murphy, Matthew L Posard, Matthew S Mcilwain, Perceptive Advisors Llc, Subramanian Sankar and Sujal M Patel.
View institutional ownership trends
.

How do I buy shares of Nautilus Biotechnology?

Shares of NAUT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NAUT) was last updated on 2/29/2024 by MarketBeat.com Staff